SUPERNUS PHARMACEUTICALS, INC. Fair Value Disclosure
Fair Value Measurements | |||||||||||||||||||||||
| Total Fair Value at December 31, 2025 | Level 1 | Level 2 | Level 3 | ||||||||||||||||||||
| Assets: | |||||||||||||||||||||||
| Cash and cash equivalents | |||||||||||||||||||||||
| Cash | $ | 56,371 | $ | 56,371 | $ | — | $ | — | |||||||||||||||
| Money market funds | 72,077 | 72,077 | — | — | |||||||||||||||||||
| Marketable securities | |||||||||||||||||||||||
| Corporate debt securities | 164,519 | — | 164,519 | — | |||||||||||||||||||
| Municipal debt securities | 14,716 | — | 14,716 | — | |||||||||||||||||||
| U.S government agency securities | 987 | — | 987 | — | |||||||||||||||||||
| Other noncurrent assets | |||||||||||||||||||||||
| Marketable securities - restricted (SERP) | 705 | 27 | 678 | — | |||||||||||||||||||
| Restricted cash | 1,450 | 1,450 | — | — | |||||||||||||||||||
| Total assets at fair value | $ | 310,825 | $ | 129,925 | $ | 180,900 | $ | — | |||||||||||||||
| Liabilities: | |||||||||||||||||||||||
| Contingent consideration | $ | 31,258 | $ | — | $ | — | $ | 31,258 | |||||||||||||||
| Total liabilities at fair value | $ | 31,258 | $ | — | $ | — | $ | 31,258 | |||||||||||||||
Fair Value Measurements | |||||||||||||||||||||||
| Total Fair Value at December 31, 2024 | Level 1 | Level 2 | Level 3 | ||||||||||||||||||||
| Assets: | |||||||||||||||||||||||
| Cash and cash equivalents | |||||||||||||||||||||||
| Cash | $ | 37,830 | $ | 37,830 | $ | — | $ | — | |||||||||||||||
| Money market funds | 31,501 | 31,501 | — | — | |||||||||||||||||||
| Marketable securities | |||||||||||||||||||||||
| Corporate debt securities | 355,201 | — | 355,201 | — | |||||||||||||||||||
| U.S. government agency debt securities | 29,080 | — | 29,080 | — | |||||||||||||||||||
| Other noncurrent assets | |||||||||||||||||||||||
| Marketable securities - restricted (SERP) | 635 | 21 | 614 | — | |||||||||||||||||||
| Total assets at fair value | $ | 454,247 | $ | 69,352 | $ | 384,895 | $ | — | |||||||||||||||
| Liabilities: | |||||||||||||||||||||||
| Contingent consideration | $ | 47,340 | $ | — | $ | — | $ | 47,340 | |||||||||||||||
| Total liabilities at fair value | $ | 47,340 | $ | — | $ | — | $ | 47,340 | |||||||||||||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 2, 2026 | Showing above |
| 2024 | Feb 25, 2025 | |
| 2023 | Feb 27, 2024 | |
| 2022 | Mar 9, 2023 | |
| 2021 | Apr 13, 2022 | |
| 2020 | Mar 8, 2021 | |
| 2019 | Feb 28, 2020 | |
| 2018 | Mar 1, 2019 | |
| 2017 | Mar 1, 2018 | |
| 2016 | Mar 16, 2017 | |
| 2015 | Mar 9, 2016 | |
About Fair Value Disclosures
Fair value disclosures classify all assets and liabilities measured at fair value into a three-level hierarchy: Level 1 (quoted market prices), Level 2 (observable inputs like yield curves), and Level 3 (unobservable inputs requiring management estimates). The proportion of Level 3 assets directly reflects how much of the balance sheet depends on internal models rather than market evidence.
Key signals: a growing Level 3 balance relative to total fair-value assets increases valuation uncertainty and earnings volatility risk. Watch for transfers between levels — assets moving from Level 2 to Level 3 often signal deteriorating market liquidity. Unrealized gains and losses on Level 3 positions flow through earnings or other comprehensive income, so large swings deserve scrutiny. For financial institutions, examine the sensitivity disclosures that show how Level 3 valuations change under alternative assumptions. Compare the fair value of debt against its carrying amount to gauge hidden leverage.